Spyre Therapeutics (SYRE) Equity Average (2016 - 2026)
Spyre Therapeutics posted quarterly Equity Average of $693.0 million for Q1 2026, up 38.55% year-on-year from $500.2 million in Q1 2025, and up 18.43% on a QoQ basis from $585.2 million in Q4 2025.
Spyre Therapeutics (SYRE) has 11 years of Equity Average data on file, last reported at $693.0 million in Q1 2026.
- For the quarter ending Q1 2026, Equity Average rose 38.55% year-over-year to $693.0 million; the trailing twelve-month figure through Mar 2026 stood at $693.0 million (up 38.55% YoY), and the FY2025 full-year result was $616.5 million, up 75.69% from the prior year.
- Equity Average for Q1 2026 stood at $693.0 million, up from $585.2 million in the prior quarter.
- Across five years, Equity Average topped out at $693.0 million in Q1 2026 and bottomed at -$226.4 million in Q3 2023.
- The 5-year median for Equity Average is $168.1 million (2024), against an average of $228.6 million.
- The widest annual swing landed in 2023, when Equity Average slumped 398.44%; it then surged 1476.85% in 2024.
- A 5-year view of Equity Average shows it stood at $58.9 million in 2022, then tumbled by 152.08% to -$30.7 million in 2023, then soared by 1476.85% to $422.6 million in 2024, then jumped by 38.47% to $585.2 million in 2025, then increased by 18.43% to $693.0 million in 2026.
- The last three Equity Average figures came in at $693.0 million (Q1 2026), $585.2 million (Q4 2025), and $455.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.34 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 932.28 Mn |
| 10 | Spyre Therapeutics | 5.55 Bn | 5.55 Bn | - | 693.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 693.02 Mn |
| Dec 31, 2025 | 585.17 Mn |
| Sep 30, 2025 | 455.44 Mn |
| Jun 30, 2025 | 469.19 Mn |
| Mar 31, 2025 | 500.21 Mn |
| Dec 31, 2024 | 422.60 Mn |
| Sep 30, 2024 | 350.89 Mn |
| Jun 30, 2024 | 263.33 Mn |
| Mar 31, 2024 | 168.14 Mn |
| Dec 31, 2023 | -30.69 Mn |
| Sep 30, 2023 | -226.39 Mn |
| Jun 30, 2023 | -86.86 Mn |
| Mar 31, 2023 | 41.98 Mn |
| Dec 31, 2022 | 58.93 Mn |
| Sep 30, 2022 | 75.86 Mn |
| Jun 30, 2022 | 72.91 Mn |
| Mar 31, 2022 | 72.80 Mn |
| Dec 31, 2021 | 93.01 Mn |
| Sep 30, 2021 | 110.55 Mn |
| Jun 30, 2021 | 121.39 Mn |
| Mar 31, 2021 | 131.79 Mn |
| Dec 31, 2020 | 138.05 Mn |
| Sep 30, 2020 | 144.27 Mn |
| Jun 30, 2020 | 97.53 Mn |
| Mar 31, 2020 | 51.44 Mn |
| Dec 31, 2019 | 69.94 Mn |
| Sep 30, 2019 | 89.71 Mn |
| Jun 30, 2019 | 107.95 Mn |
| Mar 31, 2019 | 91.86 Mn |
| Dec 31, 2018 | 65.55 Mn |
| Sep 30, 2018 | 68.56 Mn |
| Jun 30, 2018 | 58.68 Mn |
| Mar 31, 2018 | 47.13 Mn |
| Dec 31, 2017 | 52.92 Mn |
| Sep 30, 2017 | 59.06 Mn |
| Jun 30, 2017 | 59.89 Mn |
| Mar 31, 2017 | 60.07 Mn |
| Dec 31, 2016 | 65.58 Mn |
| Sep 30, 2016 | 71.06 Mn |
| Jun 30, 2016 | 23.66 Mn |
| Mar 31, 2016 | -24.41 Mn |